8-K: Capricor Therapeutics to File for FDA Approval of Deramiocel and Advances StealthX Vaccine Program

Capricor Therapeutics plans to file a Biologics License Application (BLA) for deramiocel to treat Duchenne muscular dystrophy cardiomyopathy and is progressing its StealthX vaccine program.

Summary

• Capricor Therapeutics intends to file a Biologics License Application (BLA) for deramiocel, seeking full approval for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy.
• The BLA filing will be based on existing cardiac data from the Phase 2 HOPE-2 and HOPE-2 Open Label Extension (OLE) trials, compared to natural history data.
• The company plans to combine Cohorts A and B of the Phase 3 HOPE-3 clinical trial to support potential label expansion to treat DMD skeletal muscle myopathy.
• Capricor's StealthX exosome-based vaccine for SARS-CoV-2 has been selected for Project NextGen, with manufacturing underway and delivery to NIAID expected by the end of 2024.
• A private placement with Nippon Shinyaku resulted in the sale of 2,798,507 shares at $5.36 per share, raising approximately $15.0 million.
• The company sold 5,474,550 shares under its at-the-market program at an average price of $9.84 per share, generating gross proceeds of approximately $53.9 million.
• As of September 30, 2024, Capricor estimates it had approximately $85.0 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 8

Explanation: The document is positive due to the progress in the BLA filing, the selection of the StealthX vaccine for Project NextGen, and the successful capital raises. However, the preliminary nature of the financial results and the delay in unblinding the clinical trial cohort temper the overall sentiment.

Positives

• The BLA filing for deramiocel represents a significant step towards potential FDA approval for a treatment for DMD cardiomyopathy.
• The selection of the StealthX vaccine for Project NextGen highlights the potential of Capricor's technology.
• The successful private placement and at-the-market sales have significantly strengthened the company's financial position.
• The company has a strong cash position of approximately $85.0 million as of September 30, 2024.

Negatives

• The financial results are preliminary and subject to change, and may differ materially from the company's actual financial position.
• The company has not completed its financial closing procedures for the nine months ended September 30, 2024.
• The company is combining cohorts of the Phase 3 HOPE-3 trial, which may delay the timeline for potential label expansion for DMD skeletal muscle myopathy.

Risks

• The BLA filing is subject to FDA review and approval, and there is no guarantee of success.
• The clinical trial results may not be sufficient to support the BLA filing.
• The company's financial results are preliminary and subject to change.
• The company's future results may differ materially from the preliminary estimates.
• The company's ability to deliver the StealthX vaccine to NIAID by the end of 2024 is subject to manufacturing and logistical challenges.

Future Outlook

Capricor plans to complete the BLA submission for deramiocel by the end of 2024 and deliver the StealthX vaccine to NIAID by the end of 2024. The company also intends to combine cohorts of the Phase 3 HOPE-3 trial to support potential label expansion.

Management Comments

• Capricor announced its intent to file a BLA based on existing cardiac and natural history data for deramiocel to treat all patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.
• Capricor plans to combine Cohorts A and B of the Phase 3 HOPE-3 clinical trial to serve as a post-approval study.

Industry Context

The announcement of the BLA filing for deramiocel is significant in the context of the ongoing efforts to develop treatments for Duchenne muscular dystrophy. The selection of the StealthX vaccine for Project NextGen highlights the growing interest in exosome-based vaccine technology.

Comparison to Industry Standards

• The BLA filing for deramiocel is a significant step for Capricor, placing them among companies like Sarepta Therapeutics and PTC Therapeutics that are also developing treatments for DMD.
• The use of natural history data for comparison in the BLA is a common practice in rare disease drug development, similar to approaches used by other companies in the space.
• The at-the-market program is a common method for biotech companies to raise capital, and Capricor's success in raising $53.9 million is comparable to other companies of similar size and stage.
• The $85 million cash position is a strong position for a company at this stage of development, providing a runway for further clinical trials and development.

Stakeholder Impact

• Shareholders will be impacted by the potential FDA approval of deramiocel and the progress of the StealthX vaccine program.
• The company's employees will be involved in the BLA submission and the manufacturing and delivery of the StealthX vaccine.
• Patients with DMD and their families will be impacted by the potential availability of a new treatment option.
• The company's financial position will be strengthened by the recent capital raises.

Next Steps

• Capricor will complete the BLA submission for deramiocel by the end of 2024.
• The company will deliver the StealthX vaccine to NIAID by the end of 2024.
• Capricor will combine Cohorts A and B of the Phase 3 HOPE-3 clinical trial.

Key Dates

Keywords

deramiocel, Duchenne muscular dystrophy, DMD, cardiomyopathy, StealthX vaccine, exosome, BLA, FDA, Project NextGen, NIAID, private placement, at-the-market program, clinical trial, HOPE-2, HOPE-3